Dyne Therapeutics' Global Rare-Disease Strategy Takes Shape with Japan's Orphan Nod

Dyne Therapeutics received Japan's Orphan Drug designation for zeleciment basivarsen, strengthening its global regulatory profile for treating myotonic dystrophy type 1. This recognition in a major Asian market adds to existing designations in the U.S. and Europe. The designation reinforces regulator interest but does not change the immediate binary nature of upcoming trial readouts, which are key catalysts for the company's investment narrative.